Cost-minimization Analysis of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients With Primary Immunodeficiency

Igarashi, Ataru; Kanegane, Hirokazu; Kobayashi, Midori; Miyawaki, Toshio; Tsutani, Kiichiro

doi:10.1016/j.clinthera.2014.08.007

Cited by 21 publications

(18 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Life Quality Index scores included areas such as treatment interferences with daily activities, treatment-related problems (such as convenience or painfulness of infusions), convenience of the setting in which the treatment was conducted, and costs of therapy and transportation to the location of therapy. Index scores for all domains were higher with SCIG than with IVIG [ 58 ].…”

Section: The Health-economic Impact Of High-volume Subcutaneous Biothmentioning

confidence: 99%

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities

2018

View full text Add to dashboard Cite

Subcutaneous delivery of biotherapeutics has become a valuable alternative to intravenous administration across many disease areas. Although the pharmacokinetic profiles of subcutaneous and intravenous formulations differ, subcutaneous administration has proven effective, safe, well-tolerated, generally preferred by patients and healthcare providers and to result in reduced drug delivery-related healthcare costs and resource use. The aim of this article is to discuss the differences between subcutaneous and intravenous dosing from both health-economic and scientific perspectives. The article covers different indications, treatment settings, administration volumes, and injection devices. We focus on biotherapeutics in rheumatoid arthritis (RA), immunoglobulin-replacement therapy in primary immunodeficiency (PI), beta interferons in multiple sclerosis (MS), and monoclonal antibodies (mAbs) in oncology. While most subcutaneous biotherapeutics in RA, PI, and MS are self-administered at home, mAbs for oncology are still only approved for administration in a healthcare setting. Beside concerns around the safety of biotherapeutics in oncology, a key challenge for self-administration in this area is that doses and dosing volumes can be comparatively large; however, this difficulty has recently been overcome to some extent by the development of high-concentration solutions, the use of infusion pumps, and the coadministration of the dispersion enhancer hyaluronidase. Furthermore, given the increasing number of biotherapeutics being considered for combination therapy and the high dosing complexity associated with these, especially when administered intravenously, subcutaneous delivery of fixed-dose combinations might be an alternative that will diminish these burdens on healthcare systems.

show abstract

Section: The Health-economic Impact Of High-volume Subcutaneous Biothmentioning

confidence: 99%

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities

2018

View full text Add to dashboard Cite

show abstract

“…Moreover, studies from Germany and the United States revealed that moving from IVIG to SCIG administration will decrease 50% and 88% of costs, respectively ( 12 , 13 ). In addition, studies in Sweden, Japan, and France showed less costs in SCIG than IVIG method ( 14 - 16 ). This study aimed at determining the cost-effectiveness of SCIG delivery at home compared with IVIG administration at hospital for PI patients from the perspective of the Iranian health care system.…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies

Shabaninejad

Asgharzadeh

Rezapour

et al. 2017

Med. J. Islam. Republic Iran

View full text Add to dashboard Cite

Background: Economic evaluation of subcutaneous immunoglobulin therapy (SCIG) is important, and it has recently been used for treatment of patients with primary immunodeficiency (PID) diseases, and can improve allocation of resources in health care systems. The present research aimed at providing an economic assessment of SCIG and IVIG (intravenous immunoglobulin therapy) administration in Iran. Methods: Data related to clinical effectiveness were obtained from a meta-analysis. Economic analysis was performed taking into account the perspective of health care providers. Incremental cost-effectiveness ratio (ICER) was applied for economic evaluation of the 2 methods, and GDP per capita was considered as a threshold. Results: The results of meta-analysis suggested a higher effectiveness of SCIG compared to IVIG in serum immunoglobulin (Ig) levels (SMD= 0.336) and adverse effects (OR= 0.497), while the cost of IVIG was higher than SCIG ($1370 vs. $121). The ICER obtained in this paper ($2939 for adverse effects and $4348 for serum Ig level) was less than the GDP per capita in Iran ($4,916.10), and thus SCIG is a more cost-effective therapy for PID patients. Conclusion: Switching from IVIG to SCIG is cost-effective for PID patients and is approved by the health care providers’ points of view in this study.

show abstract

“…A recent review of 25 studies noted that 4 studies evaluating health economics in SCIG and IVIG therapy all found SCIG to be more cost effective, mainly through the reduction of lost work or school days [ 48 ]. Other studies have shown that SCIG is more cost effective due to issues with IVIG such as personnel required to administer, facility rooms, administrative overheads and productivity loss [ 42 , 49 , 50 ]. In comparison to patients on IVIG, patients on SCIG miss significantly fewer days of work or school [ 51 , 52 ] and one study also noted they spend significantly fewer days in the hospital [ 51 ].…”

Section: Introductionmentioning

confidence: 99%

Health-related quality of life in patients with primary immunodeficiency disease

Jiang

Torgerson

Ayars

2015

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

Primary immunodeficiency disease (PIDD) with hypogammaglobulinemia is characterized by recurrent and severe bacterial infections and IgG replacement is the standard of care in many of these patients. Health-related quality of life (HRQOL) is becoming increasingly recognized as a factor that affects patient well-being and treatment preferences. In an effort to better understand what factors affect HRQOL in patients with PIDD, we reviewed the published literature that used standardized instruments for the measurement of HRQOL. We investigated HRQOL in PIDD patients compared with normal controls and patients with other chronic diseases; we also investigated the impact of treatment administration on patient satisfaction. The most commonly encountered health-related quality of life instruments were the child heath questionnaire parental form 50, short form 36, PedsQL 4.0, Lansky’s play performance scale, and Life Quality Index. Patients with PIDD scored significantly lower on many of the instruments compared with normal controls. Also, while it appears that many patients appreciate home-based and subcutaneous IgG replacement therapy, patient satisfaction ultimately involves various clinical factors and individual patient preferences. By further analyzing what factors impact HRQOL, therapy adjustments can be made to maximize patient well-being and minimize disease impact on daily functioning.

show abstract

Cost-minimization Analysis of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients With Primary Immunodeficiency

Cited by 21 publications

References 22 publications

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities

Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies

Health-related quality of life in patients with primary immunodeficiency disease

Contact Info

Product

Resources

About